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The response to treatment was about 20%
higher in the clinical trial group. The 20%
difference between the outcomes in the
prospective and retrospective studies recorded
in the response to treatment was similar in the 1,
2, and 3 years local controi observations.
62.
THE RADIOTHERAPY OF IMRT
S.M. Bentzen
Gray Institute of Cancer Research, Mount
Vernon Hospital, Northwood, Middlesex, UK
Intensity Modulated Radiotherapy (IMRT) is
going to revolutionise treatment planning and
delivery of radiotherapy in the next few years.
Although there are still technological constraints,
IMRT allows delivery of a specified dose-
distribution that is superior to what is realistically
achievable with 3D conformal radiotherapy
using standard techniques. This forces a re-
think of the whole process of delivering
radiotherapy. With our current technology, the
physics has overtaken the biology and it
appears that to realise the fuli potential of IMRT,
a major research effort on the biological aspects
of radiotherapy is needed. This goes far beyond
traditional cellular radiobiology. New powerful
assays in molecular biology and bioimaging will
be key elements in the biological optimisation of
radiotherapy. In this lecture, I will try to identify
some of the research areas that will need to be
further developed in order to get the fuli
therapeutic benefit from IMRT.
63.
STEREOTACTIC RADIOTHERAPY
FOR PRIMARY AND RECURRENT
BRAIN TUMORS. A NEW METHOD
FOR IMPROVEMENT OF THE
TREATMENT RESUlTS?
J. Fijuth
Centrum Onkologii - Instytut, Warszawa
To evaluate the effectiveness of the
stereotactic radiosurgery (SRS) and stereotactic
fractionated radiotherapy in the primary,
recurrent and metastatic brain tumors.
To present potential usefulness of stereotactic
boost in anaplastic astrocytomas (AA) and
glioblastoma multiforme (GBM).
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Between March 2000 and December 2000,
SRS was applied in 23 patients (pts) with brain
tumors (metastatic tumors - 9 pts, recurrent
tumors - 7 pts, primary meningiomas - 4 pts,
vascular malformations - 3 pts).
Fractionated stereotactic radiotherapy was
applied in 6 pts (recurrent anaplastic gliomas - 2
pts, recurrent medulloblastoma - 1 pt, acustic
neurinoma - 1 pt, meningioma - 1, pituitary
adenoma - 1).
Detailed technique of treatment planning is
presented and discussed. The planning target
volume (PTV) and organs at risk (OAR) were
assessed comparing dose statistics, dose
volume histograms and RTOG stereotactic
radiosurgery criteria.
Recommendations regarding the total dose
level and fractional dose are proposed.
The treatment tolerance and preliminary results
are presented.
The own protocol of stereotactic boost to
residual tumor using SRS after initial conformal
radiotherapy in patients with AA and GBM is
presented and discussed.
64.
STATE OF MONTE CARLO
CAlCUlATIONS IN RADlATlON
TREATMENT PlANNING
U. Rosenow
Instytut: Georg-August-Universitat Gottingen
Department for Clinical Radiation Biology and
Clinical Radiation Physics Gottingen
Monte Carlo (MC) particie transport
simulations are increasingly applied in treatment
planning methods. This has become feasible
through a number of adaptations of general MC
codes, such as EGS4 ar ETRAN, to the specific
needs of treatment planning. The currently most
advanced "conventional" planning methods,
such as convolution or delta-volume algorithms
still have serious limitations in terms of accuracy
when tissue inhomogeneities, smali and
complex body shapes or high-density implants
are involved. The Monte Carlo simulation
mimics individual particie transport, in any
applicable geometry, by applying first principles
of radiation interaction with matter and random
choice of collision parameters such as step
length, type of interaction, energies and
scattering angles. In principle, the accuracy of
MC calculations is only Iimited the radiation
beam quality definition and the interaction
parameters and can be taken to below 12%. In
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